The GSK name and elements of the incumbent orange logo have been retained in the new identity. Stevens says that the decision to retain the orange was partly driven by the fact that “the world of ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...

(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued ...